Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Dickson

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2021
TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibitionSarah Chiang, Varshini Vasudevaraja, Jonathan Serrano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M Gounder, Alona Zer, William D Tap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, Li-Xuan Qin, Niedzica Camacho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Cancer Research Communications|December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated LiposarcomaEvan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Lancet (London, England)|November 15, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trialYvonne M Mowery, Karla V Ballman, Angela M Hong, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2021
TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibitionSarah Chiang, Varshini Vasudevaraja, Jonathan Serrano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M Gounder, Alona Zer, William D Tap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, Li-Xuan Qin, Niedzica Camacho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Cancer Research Communications|December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated LiposarcomaEvan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Lancet (London, England)|November 15, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trialYvonne M Mowery, Karla V Ballman, Angela M Hong, et al.
Pageof 8